You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2024

~ Buy the XERAVA (eravacycline dihydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

XERAVA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Xerava patents expire, and what generic alternatives are available?

Xerava is a drug marketed by Tetraphase Pharms and is included in one NDA. There are four patents protecting this drug.

This drug has eighty-four patent family members in thirty-three countries.

The generic ingredient in XERAVA is eravacycline dihydrochloride. One supplier is listed for this compound. Additional details are available on the eravacycline dihydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Xerava

Xerava was eligible for patent challenges on August 27, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 19, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for XERAVA?
  • What are the global sales for XERAVA?
  • What is Average Wholesale Price for XERAVA?
Summary for XERAVA
International Patents:84
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 27
Clinical Trials: 1
Patent Applications: 102
Drug Prices: Drug price information for XERAVA
What excipients (inactive ingredients) are in XERAVA?XERAVA excipients list
DailyMed Link:XERAVA at DailyMed
Drug patent expirations by year for XERAVA
Drug Prices for XERAVA

See drug prices for XERAVA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for XERAVA
Generic Entry Date for XERAVA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XERAVA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
West Virginia UniversityPhase 2

See all XERAVA clinical trials

Pharmacology for XERAVA

US Patents and Regulatory Information for XERAVA

XERAVA is protected by four US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of XERAVA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting XERAVA

Crystalline forms of eravacycline
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

C7-fluoro substituted tetracycline compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER

C7-fluoro substituted tetracycline compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting XERAVA

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for XERAVA

When does loss-of-exclusivity occur for XERAVA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

Patent: 0582486
Patent: 艾若威四环素的结晶形式 (CRYSTALLINE FORMS OF ERAVACYCLINE)
Estimated Expiration: ⤷  Sign Up

Patent: 7903083
Patent: 艾若威四环素的结晶形式
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 29236
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 29236
Patent: FORMES CRISTALLINES DE L'ÉRAVACYCLINE (CRYSTALLINE FORMS OF ERAVACYCLINE)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 19531321
Patent: エラバサイクリンの結晶形
Estimated Expiration: ⤷  Sign Up

Patent: 22186979
Patent: エラバサイクリンの結晶形
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 567
Patent: FORMES CRISTALLINES DE L'ÉRAVACYCLINE
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 019500822
Patent: CRYSTALLINE FORMS OF ERAVACYCLINE
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201903327P
Patent: CRYSTALLINE FORMS OF ERAVACYCLINE
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2660864
Estimated Expiration: ⤷  Sign Up

Patent: 190065414
Patent: 에라바사이클린의 결정질 형태
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XERAVA around the world.

Country Patent Number Title Estimated Expiration
Denmark 3529236 ⤷  Sign Up
Denmark 2323972 ⤷  Sign Up
Spain 2558512 ⤷  Sign Up
South Korea 20110058800 C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS ⤷  Sign Up
Hong Kong 1222840 -氟取代的四環素化合物 (C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS C7-) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XERAVA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2323972 LUC00107 Luxembourg ⤷  Sign Up PRODUCT NAME: ERAVACYCLINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924
2323972 2019010 Norway ⤷  Sign Up PRODUCT NAME: ERAVASYKLIN ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV; REG. NO/DATE: EU/1/18/1312 20181025
2323972 CA 2019 00009 Denmark ⤷  Sign Up PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209
2323972 CR 2019 00009 Denmark ⤷  Sign Up PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209
2323972 300971 Netherlands ⤷  Sign Up PRODUCT NAME: ERAVACYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/18/1312 20180924
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.